Geron Corp (GERN) is trading 9% higher at $2.375 today. The stock is strongly outrunning peers on a mildly dispirited day for the Health Care sector.

The price move is likely being affected by the fact that the company reported earnings 77 days ago.

Geron Corp has been trading between a 52-week high of $2.67 and a 52-week low of $0.9899. The stock has a market cap of $897 Million.

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Geron Corporation (NASDAQ: GERN) Can Raise Stock 1.83% More
Stocks Register 08-22-22

Geron rises on narrower-than-expected Q2 loss
Seeking Alpha 08-12-22

Geron (GERN) Q2 2022 Earnings Call Transcript
The Motley Fool 08-11-22

Geron Corporation''s (GERN) CEO Dr. John Scarlett on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha 08-11-22

Geron Corporation 2022 Q2 - Results - Earnings Call Presentation (NASDAQ:GERN)
Seeking Alpha 08-11-22